Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
Effectiveness Of Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
This study performed to evaluate and compare the effectiveness ofextended platelet-rich fibrin (ePRF) and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The phenomenon of horizontal and vertical ridge resorption, following tooth extraction, has been extensively investigated. Different augmentation techniques have been developed to overcome this phenomenon on localization, extent, and configuration of the bone defect. These include insertion of bone grafts or barrier membranes in terms of guided bone regeneration.
The advancement Of guided bone regeneration has significantly expanded the range of implant applications to be a highly reliable treatment option even in areas of the jaw bone don't have sufficient bone support.The predictability that just attained if this process is successful, it could change the treatment of a compromised patient into a nearly normal challenge. Various have described to reconstruct deficient alveolar ridges. In the simultaneous treatment approach, guided bone regeneration is associated with superior outcomes when compared to other procedures and has become the treatment Of choice to provide optimal support for dental implants.
The primary alternative to an autograft is the use of allograft materials, which can obtained from either a compatible living donor or from cadaveric bone sources. Allograft materials can be prepared in three primary forms: fresh, frozen, or freeze-dried. Fresh and frozen allograft materials possess superior osteoinductive but are rarely used nowadays due to the higher risk Of a host immunogenic response, limited shelf life, and increased risk of disease transmission. Further processing of allograft material through freeze-drying can increase the shelf life of the material and decrease the immunogenicity, though at the cost of decreased osteoinductive potential, decreased structural strength, and osseointegration. Allografts have been successfully used for guided bone regeneration in bone augmentation procedure. This study performed to evaluate and compare the effectiveness of extended platelet-rich fibrin and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Al Mansurah, 이집트
- Mansoura university
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Horizontal bone width <6 mm an s than 3 mm at crest
- Sufficient vertical bone height for implant placement.
- Healthy and sufficient width Of keratini7Æd mucosa.
- Maxillary or mandibular edentulous space sufficient for prosthesis according to teeth to be restored. All patients are between 18 and 60 years
Exclusion Criteria:
- General contraindication for implant placement and/or surgical treatment.
- Ongoing Inflammatory and/or autoimmune disease of the oral cavity.
- Immunosuppressant, corticosteroid or bisphosphonate therapy.
- History of malignancy, radiotherapy or chemotherapy for treatment of malignancy within the past 5 years.
- Smokers.
- Insulin- dependent diabetes
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Group l
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration and pericardium membrane (maxxeus). |
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and pericardium membrane (maxxeus). |
|
실험적: Group II
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by dried freeze allograft and (e-PRF) membrane |
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft part of Straumann Group, Basel, Switzerland) and (e-PRF) membrane. |
|
실험적: Group III
Group III: It will include 10 patients and they will treated with delayed implant placement combined with GBR by dried freeze bone allograft DFBA and novel magnesium membrane NOVAMag |
roup III: It will include 10 patients and they will treated with delayed implant placement combined with guided bone regeneration by dried freezed bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and novel magnesium membrane NOVAMag |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Radiographic assessment by cone beam computed tomography
기간: immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Status of the peri-implant soft tissues (probing depth )
기간: 2 months and 6 months after loading.
|
2 months and 6 months after loading.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- A010120230M
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
It will be available if it needed
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .